

REMARKS

Following entry of the above amendment, claims 2-7 are pending. Claim 1 has been cancelled. New claims 4-7 have been added. Support for the new claims can be found in the specification as originally filed. See, for example, pages 52-55 and the example and procedures therein.


The Office Action states that the instant application contains inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1 and requires Applicants to elect a single invention from the following groups:

Group I: Claim 1, drawn to process of making compounds of formula (R);
and

Group II: Claims 2-3, drawn to process of making compounds of formula (I).

Applicants elect, without traverse, **Group II** including claims 2-7. Applicants note that new claims 4-7 are within the scope of claims 2-3 and respectfully request that they be included in Group II.

The Office Action states that Applicants must provisionally elect a species from Group II for purposes of examination. Applicants provisionally elect the species of Example 1 on page 52 of the specification, also known by the formula:



Applicants respectfully request entry of the above amendment and examination of claims 2-7. Additionally, Applicants believe the present claims are in condition for allowance and such action is respectfully requested. Applicants believe that no other fees are due in connection with the filing of this paper other than those specifically authorized herewith.

Should any other fees be deemed necessary to effect the timely filing of this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account

No. 07-1392. If the Examiner has any outstanding issues with the pending claims, the examiner is encouraged to telephone the undersigned at (919) 483-6334 for expeditious handling.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'J. Fox', written over a horizontal line.

Jennifer L. Fox
Attorney for Applicant
Registration No. 52,218

Date: 8 Nov 07
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-6334
Facsimile: (919) 483-7988